LONDON, Nov 19 (Reuters) - Anglo-Swedish drugmaker AstraZeneca revealed mixed results from a late-stage cancer drug trial on Wednesday and said rival Teva has won approval for a generic version of its asthma drug Pulmicort.
LONDON, Nov 19 (Reuters) - Anglo-Swedish drugmaker AstraZeneca revealed mixed results from a late-stage cancer drug trial on Wednesday and said rival Teva has won approval for a generic version of its asthma drug Pulmicort.